Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer

Purpose: The aim of the study was to assess quality of life (QoL), decision involvement, and decisional regret after treatment with vascular-targeted photodynamic therapy (VTP) (TOOKAD®) for unilateral low-risk prostate cancer. Methods: Validated questionnaires (EORTC QLQ-C30 and QLQ-PR25) capturing QoL post-treatment, involvement in decision-making (Control Preferences Scale) and decision regret (Decisional Regret Scale), were given to patients at the 12-month visit after undergoing VTP at our institution between May 2018 and February 2021. Results: Out of 44 patients, 36 patients were included in this study and 31 (86.1%) responded to the questionnaires. Mean overall health score capturing QoL at 12 months was 79.3 (standard deviation: ±18.1). 70.9% of the patients (n = 22) had no decision regret, and 67.8% of men (n = 21) had an active role in decision-making. In control biopsy at 12 months post-treatment, 19.4% of patients (n = 7) presented with local recurrence and progression to higher Gleason score (GS) was found in 13.8% of patients (n = 5). Patients (n = 3) presenting with tumor recurrence or progression to higher GS in control biopsy showed a significantly higher level of decision regret (p < 0.009). Conclusion: Only 9.7% of men (n = 3) felt a strong emotion of regret at 12 months after VTP. Level of decision regret was significantly higher in patients with local recurrence or tumor progression detected in control biopsy. QoL was stable after VTP.

[1]  J. Huber,et al.  Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy. , 2021, European urology focus.

[2]  J. von Hardenberg,et al.  Treatment decision satisfaction and regret after focal HIFU for localized prostate cancer , 2020, World Journal of Urology.

[3]  L. Weissbach,et al.  Decision Regret after Radical Prostatectomy Does Not Depend upon Surgical Approach: 6-Year Follow-Up of a Large German Cohort Undergoing Routine Care. , 2020, The Journal of urology.

[4]  P. Scardino,et al.  Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness , 2018, The Journal of urology.

[5]  H. G. van der Poel,et al.  Shared Decision Making in Prostate Cancer Care—Encouraging Every Patient to be Actively Involved in Decision Making or Ensuring the Patient Preferred Level of Involvement? , 2018, The Journal of urology.

[6]  H. G. van der Poel,et al.  Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. , 2018, European urology.

[7]  J. Steurer,et al.  The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation , 2018, Health and Quality of Life Outcomes.

[8]  F. Kendel,et al.  ["Dr. Google"-information-seeking behavior and disease-specific anxiety among men with localized prostate cancer]. , 2018, Der Urologe. Ausg. A.

[9]  C. Porter,et al.  Longitudinal regret after treatment for low‐ and intermediate‐risk prostate cancer , 2017, Cancer.

[10]  J. Stanford,et al.  Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Podder,et al.  Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review. , 2017, Future oncology.

[12]  Antonio Alcaraz,et al.  Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. , 2017, The Lancet. Oncology.

[13]  B. Hadaschik,et al.  Quality of life and functional outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer , 2017, BMC Urology.

[14]  S. Stagni,et al.  “What if…”: Decisional Regret in Patients who Discontinued Active Surveillance , 2016, Tumori.

[15]  S. Taneja,et al.  Focal therapy for prostate cancer: The current status , 2015, Prostate international.

[16]  A. Gavin,et al.  Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study , 2015, Journal of Cancer Survivorship.

[17]  C. Pettaway,et al.  Treatment regret and quality of life following radical prostatectomy , 2013, Supportive Care in Cancer.

[18]  H. Ahmed,et al.  Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study , 2012, The Lancet. Oncology.

[19]  J. Rewcastle,et al.  Focal therapy for the treatment of localized prostate cancer: a potential therapeutic paradigm shift awaiting better imaging , 2012, Current opinion in urology.

[20]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[21]  M. Diefenbach,et al.  Regret of Treatment Decision and its Association with Disease-Specific Quality of Life Following Prostate Cancer Treatment , 2007, Cancer investigation.

[22]  Deb Feldman-Stewart,et al.  Validation of a Decision Regret Scale , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[23]  B. Davison,et al.  Decisional regret and quality of life after participating in medical decision‐making for early‐stage prostate cancer , 2003, BJU international.

[24]  A. Hinz,et al.  Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. , 2001, European journal of cancer.

[25]  C. Ashton,et al.  Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J A Sloan,et al.  The Control Preferences Scale. , 1997, The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres.